Diamond Capital Management
W252N4915 Aberdeen Drive, Pewaukee, WI, 53072, United States
Overview
Diamond Capital Management is dedicated to offering clients well managed alternative investment products that offer consistent returns and protection of principal achieved through the proper application of money management and continuous evaluation of risk exposure. The principals at Diamond Capital have a solid understanding of the markets and the instruments utilized in the strategies. Past experience has demonstrated that using modifications of tried and true concepts such as proper portfolio diversification, diligent adaptation to market volatility, dollar-cost-averaging with judicious profit taking throughout the investment term, among others, hold the most promise. Our success is measured against other investment benchmarks, as well as peer group and related industry benchmarks. While short-term performance is always difficult to predict, our long-term goal is to provide consistently attractive returns, within reasonable risk parameters. In doing so, we at Diamond Capital take personal pride in managing accounts with our clients' best interest in mind. Diamond Capital Management, LLC, ("DCM") is registered with the Commodity Futures Trading Commission ("CFTC") as a Commodity Trading Advisor ("CTA") and is a member of the National Futures Association ("NFA"). We invite you to investigate Diamond's strategies further and discover a non-correlated alternative investment products to compliment your long term investment goals. To learn more about Diamond Capital and the potential value DCM can add to your overall portfolio, please explore our site, or contact us directly. Past performance is not necessarily a representation of future results. Alternative investments such as managed futures investments are speculative, involve substantial risk, and are not suitable for all investors.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
Investment portfolio
- CytoPherx
Led · Series B · Jun 2010
CytoPherx develops a proprietary Selective Cytopheretic Device (SCD) that is added to the renal replacement circuit to modulate acute systemic inflammation in ICU patients with kidney injury. The company is clinical-stage and pursuing U.S. regulatory approval to commercialize its anti-inflammatory therapy for acute kidney injury. Management reports early trials showing potential mortality reductions of as much as 15% in critically ill patients. CytoPherx has initiated a 344-patient pivotal trial across leading U.S. nephrologists and institutions, with a primary endpoint of reduced mortality through day 60 and secondary evaluations including severe sepsis, ARDS, and long-term dialysis dependence. The company says the target population represents over 2.7 million hospitalized U.S. patients diagnosed with acute renal failure annually, with roughly 160,000 receiving Continuous Renal Replacement Therapy, a multi-billion dollar market opportunity. CytoPherx was founded in July 2007 and is headquartered in Ann Arbor, Michigan. CytoPherx develops hollow-fiber dialysis filters designed to isolate and deactivate white blood cells in patients’ bloodstreams to treat renal failure and inflammation from cardiopulmonary bypass. The company is a University of Michigan spinoff, founded in 2007 and previously known as Nephrion Inc., based in Ann Arbor, Mich. The recent funding will support a clinical trial for its filters; CytoPherx began enrolling patients last month and expects to complete enrollment by the end of June. The current financing is part of an anticipated $7.5M Series B, with $5M already raised. The new funds are structured as equity, debt and warrants and were sourced from five investors. To date, the company has raised $12M in total lifetime funding.
Team
No current team members are available.